Quantcast

Montana Settles Risperdal Lawsuit for $5.9 Million

Janssen To Pay $5.9 Million Settlement to Montana for Misleading Ads In March of this year, Montana State Attorney General Tim Fox announced that Johnson & Johnson’s subsidiary Janssen Pharmaceuticals agreed to pay $5.9 million to settle allegations in the state regarding its antipsychotic drug, Risperdal. Like many Risperdal settlements in … [Read more...]

Former FDA Chief Testified J&J Knew Risperdal Dangers

Ex-FDA Chief Testified in Risperdal Trial that J&J Knew About Dangerous Side Effects According to testimony in the current Risperdal trial, Johnson & Johnson knew as early as 2001 that it’s antipsychotic drug had serious, dangerous side effects, including that it could cause gynecomastia (female breast tissue growth) in young boys. Former … [Read more...]

J&J Wins Cut in South Carolina Risperdal Judgment

J&J Successfully Gets South Carolina Risperdal Judgement - Damages Cut in Half Although Johnson & Johnson, and its subsidiary Janssen Pharmaceuticals, face thousands of Risperdal personal injury lawsuits combined in a multidistrict litigation (MDL) in Philadelphia, the companies are fighting previous penalties for off-label use in numerous … [Read more...]

Risperdal Lawsuit Ends in Win for Plaintiff, But No Damages

Jury Finds Risperdal Caused Plaintiff’s Gynecomastia, But Awards No Financial Damages On Friday, March 20th, the jury for the latest Risperdal personal injury lawsuit ruled that Johnson & Johnson failed to warn doctors and patients of the risks of using Risperdal for off-label prescriptions, which led to the plaintiff’s gynecomastia; however, … [Read more...]

Risperdal Personal Injury Lawsuits Growing in Number

Johnson & Johnson Faces Numerous, Serious Personal Injury Lawsuits Due to Taking Risperdal In September, Johnson & Johnson issued a recall notice for Risperdal Consta, a long-acting form of the anti-psychotic drug, Risperdal. At the time, the pharmaceutical manufacturer believed that there were no injuries as a result of taking the … [Read more...]

Opening Arguments Begin in Risperdal MDL Injury Case

Risperdal MDL in Philadelphia Begins Opening Arguments On Friday, January 23rd, the Risperdal MDL (multidistrict litigation) alleging long-lasting personal injury caused by the drug Risperdal, when used for off-label purposes, began in Philadelphia. Opening arguments debated the specific personal injury claim that using Risperdal in young boys … [Read more...]

Risperdal Judgment Reversed in Arkansas

J&J Wins Reversal of Risperdal Penalty in Arkansas On Thursday, March 20th, Johnson & Johnson won a reversal of their $1.2 billion penalty against their drug Risperdal in Arkansas Supreme Court. In 2012, an Arkansas jury agreed that J&J and Janssen Pharmaceuticals misled Arkansas’s doctors regarding Risperdal’s safety. The judgment … [Read more...]

Amgen Pays $71 Million for Promoting Off-Label Drug Uses

Pharmaceutical Giant Amgen Pays States to Settle Illegal Promotion of Off-Label Uses for Drugs Biotech and pharmaceutical company Amgen has agreed to pay 48 states a settlement amount of $71 million after a group of attorneys general claimed the company intentionally promoted off-label uses for two of its major drugs. Amgen had been accused of … [Read more...]

$70 Million Verdict Against J&J in Risperdal Trial

Largest Verdict Thus Far Against Jansen for $70 Million in Risperdal Trial According to Reuters, Janssen Pharmaceuticals, a unit of Johnson & Johnson, was hit with a $70 million verdict in a Risperdal trial last week, marking the largest verdict against Janssen thus far in this ongoing litigation. The award was handed down in the case of a 15 … [Read more...]

Johnson & Johnson to Appeal Risperdal Fine

J&J and Janssen Pharmaceuticals to Appeal Arkansas’s Risperdal Fine In April 2012, jurors in Arkansas agreed that Johnson & Johnson, and its subsidiary Janssen Pharmaceuticals, misled Arkansas’s doctors and patients about the risks of the anti-psychotic drug, Risperdal. Now, J&J has filed to appeal that ruling, and oral arguments … [Read more...]

BestLawyers.comAVBetter Business Bureau